Browse IFNAR2

Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 2: Cell membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 3: Secreted
Domain PF09294 Interferon-alpha/beta receptor
PF01108 Tissue factor
Function

Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation (PubMed:26424569). Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1 (PubMed:8181059, PubMed:7665574, PubMed:7759950). Isoform 3 is a potent inhibitor of type I IFN receptor activity (PubMed:7759950).

> Gene Ontology
 
Biological Process GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0007259 JAK-STAT cascade
GO:0009615 response to virus
GO:0034340 response to type I interferon
GO:0035455 response to interferon-alpha
GO:0035456 response to interferon-beta
GO:0045088 regulation of innate immune response
GO:0051607 defense response to virus
GO:0060337 type I interferon signaling pathway
GO:0060338 regulation of type I interferon-mediated signaling pathway
GO:0060759 regulation of response to cytokine stimulus
GO:0071357 cellular response to type I interferon
GO:0097696 STAT cascade
GO:0098542 defense response to other organism
Molecular Function GO:0004896 cytokine receptor activity
GO:0004904 interferon receptor activity
GO:0004905 type I interferon receptor activity
GO:0019955 cytokine binding
GO:0042015 interleukin-20 binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04380 Osteoclast differentiation
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
R-HSA-912694: Regulation of IFNA signaling
Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IFNAR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IFNAR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.37; FDR: 0.000424 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 8.95; FDR: 0.000 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 7.84; FDR: 0.000 Sensitive to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IFNAR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.20.512
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5410.776
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0530.968
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0140.959
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0290.987
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0090.997
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1460.691
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0090.995
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3410.809
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3320.817
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8270.703
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0050.953
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IFNAR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IFNAR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IFNAR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IFNAR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IFNAR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IFNAR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IFNAR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIFNAR2
Nameinterferon (alpha, beta and omega) receptor 2
Aliases IFNABR; IFN-R; IFNARB; IFN-R-2; IFN-alpha/beta receptor 2; human interferon alpha/beta receptor; interferon ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IFNAR2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IFNAR2.
ID Name Drug Type Targets #Targets
DB00008Peginterferon alfa-2aBiotechIFNAR1, IFNAR22
DB00011Interferon alfa-n1BiotechIFNAR1, IFNAR22
DB00018Interferon alfa-n3BiotechIFNAR1, IFNAR22
DB00022Peginterferon alfa-2bBiotechIFNAR1, IFNAR22
DB00034Interferon Alfa-2a, RecombinantBiotechIFNAR1, IFNAR22
DB00060Interferon beta-1aBiotechIFNAR1, IFNAR22
DB00068Interferon beta-1bBiotechIFNAR1, IFNAR22
DB00069Interferon alfacon-1BiotechIFNAR1, IFNAR22
DB00105Interferon Alfa-2b, RecombinantBiotechIFNAR1, IFNAR22
DB05472omega interferonSmall MoleculeIFNAR1, IFNAR22